CSGALNACT2P2

Across TCGA pan-cancer cohorts, CSGALNACT2P2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CSGALNACT2P2 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher CSGALNACT2P2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CSGALNACT2P2 expression acts as an unfavorable survival marker.

LAML are the cancer types where CSGALNACT2P2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Median	All	0.112	0.582	.010	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

CSGALNACT2P2–LAML (DFS)

Open the LAML breakdown →